Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

NCT00031187 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: SGN-15 (cBR96-doxorubicin immunoconjugate)
DRUG: Taxotere (docetaxel)

Sponsor

Seagen Inc.